Physician profile
Janeen E Constantine
NPI 1720198302
$2,487.91
in general payments reported to CMS, 2019-2025
15 companies · $685 in 2025
The $685 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $405 · 2023: $184 · 2024: $1,026 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,115.92 | 2021-2025 | Lifevest |
| Abbott Laboratories | $415.43 | 2024-2025 | Aveir, Cardiomems |
| Amgen INC. | $230.92 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $133.91 | 2022-2025 | Eliquis |
| Scpharmaceuticals INC. | $115.72 | 2025 | |
| Novo Nordisk INC | $95.51 | 2024-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.22 | 2021-2024 | Jardiance |
| Pfizer INC. | $64.15 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $61.86 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $51.40 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $35.99 | 2021-2022 | |
| Boston Scientific Corporation | $30.94 | 2025 | Upsylon |
| Celgene Corporation | $21.90 | 2024 | Reblozyl |
| Philips North America LLC | $18.06 | 2024 | (Ck4) Mcot |
| Chiesi USA, INC. | $14.98 | 2024 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janeen Constantine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.